Sign In
Buy PFE
$26.04
+0.345 (+1.34%)
At Close: Jun 05, 2026
Buy 3 High Dividend-Paying Stocks With Attractive Short-Term Returns
03:01pm, Monday, 16'th Sep 2024
Three large-cap stocks ??? AES, PFE and UNM?
Pfizer Drug Treating Fatal Weight Loss in Cancer Patients Found Effective
09:12am, Monday, 16'th Sep 2024
Pfizer (PFE) said this weekend that a drug aimed at helping cancer patients losing appetite and muscle mass showed positive results in a Phase 2 trial.
International ID Day: Thales Stands up for a Legal and Trusted Identity for Everyone
02:00am, Monday, 16'th Sep 2024
MEUDON, France--(BUSINESS WIRE)-- #ThalesIDWallet--On September 16th, Thales celebrates the International Identity Day (ID Day), a symbolic day to highlight the United Nations' Sustainable Development
Is Pfizer's 5.7% Dividend Yield Worth the Risk?
07:00am, Sunday, 15'th Sep 2024
Pfizer's 5.7% dividend yield stands out in the healthcare sector. The company's 436% payout ratio raises concerns about dividend sustainability.
Pfizer said its experimental drug for a common, life-threatening condition that causes cancer patients to lose their appetite and weight showed positive results in a midstage trial. Patients with the
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
08:45am, Saturday, 14'th Sep 2024
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary e
Pfizer pushing BRAF lung cancer mutation testing to grow market for Braftovi
04:32am, Saturday, 14'th Sep 2024
Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates could grow to become the
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (enc
5 Bargain Price-to-Sales Stocks With High Growth Prospects
09:15am, Friday, 13'th Sep 2024
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like GIII, BTU, HG, BBSI and PFE hold promise.
Got $5,000? 3 Dirt Cheap Stocks to Buy Right Now
08:30am, Friday, 13'th Sep 2024
Finding stocks that trade at discounts can set investors up for significant gains in the long run. The stocks listed here are facing headwinds right now, but their growth prospects remain promising.
A Bull Market Is Here: 2 High-Potential Stocks Down More Than 50% to Buy Right Now
07:30am, Friday, 13'th Sep 2024
Moderna may have a number of new product launches ahead. Pfizer is a big pharma stock that's poised for a big comeback.
Pfizer Stock Vs. AbbVie
06:00am, Friday, 13'th Sep 2024
Given its better valuation, we believe that Pfizer stock (NYSE: PFE) is currently a better pick than its industry peer – AbbVie stock . PFE stock trades at a much lower multiple of 11x forward, vers
Boost Your Portfolio's Health With These 4 Large-Cap Drug Stocks
11:50am, Thursday, 12'th Sep 2024
Here are four big drug/biotech stocks, LLY, RHHBY, NVS and PFE, which you should buy today for lucrative long-term returns.
5 High-Yield Dividend Stocks That Pay 5% and More to Buy Now and Hold Forever
08:48am, Thursday, 12'th Sep 2024
24/7 Wall St. Insights September is here, and the Federal Reserve is expected to lower rates for the first time in years.
Pfizer (PFE) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Wednesday, 11'th Sep 2024
Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
